|
|
Volumn 39, Issue 2, 1999, Pages 236-238
|
|
First MAb approved for treatment of metastatic breast cancer.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
ANIMAL;
BREAST TUMOR;
CLINICAL TRIAL;
DRUG APPROVAL;
FEMALE;
HUMAN;
PATHOLOGY;
REVIEW;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CLINICAL TRIALS;
DRUG APPROVAL;
FEMALE;
HUMANS;
RECEPTOR, ERBB-2;
MLCS;
MLOWN;
|
|
EID: 0033093978
PISSN: 10865802
EISSN: None
Source Type: Journal
DOI: 10.1016/s1086-5802(16)30498-3 Document Type: Review |
|
Times cited : (39)
|
|
References (12)
|
